


Tenoxicam

Cat. No.:	HY-B0440		
CAS No.:	59804-37-4		
Molecular Formula:	C ₁₃ H ₁₁ N ₃ O ₄ S ₂		
Molecular Weight:	337.37		
Target:	COX		
Pathway:	Immunology/Inflammation		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : 50 mg/mL (148.21 mM; Need ultrasonic)
 H₂O : < 0.1 mg/mL (insoluble)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	2.9641 mL	14.8205 mL	29.6410 mL
	5 mM	0.5928 mL	2.9641 mL	5.9282 mL
	10 mM	0.2964 mL	1.4821 mL	2.9641 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
 Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
 Solubility: 2.5 mg/mL (7.41 mM); Suspended solution; Need ultrasonic
- Add each solvent one by one: 10% DMSO >> 90% corn oil
 Solubility: ≥ 2.5 mg/mL (7.41 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Tenoxicam (Ro-12-0068), an antiinflammatory agent with analgesic and antipyretic properties.

IC₅₀ & Target

COX-1

COX-2

In Vitro

Tenoxicam (Ro-12-0068) is a non-steroidal anti-inflammatory drug (NSAID)^[1].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Tenoxicam (Ro-12-0068) was administered intraperitoneally immediately after BCAA. Histological analyses show that ischemia produced significant striatal as well as hippocampal lesions which were reversed by the Tenoxicam (Ro-12-0068) treatment. Tenoxicam (Ro-12-0068) also significantly reduced, to control levels, the increased myeloperoxidase activity in hippocampus homogenates observed after ischemia^[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Ozgocmen, S., et al., In vivo effect of celecoxib and tenoxicam on oxidant/ anti-oxidant status of patients with knee osteoarthritis. Ann Clin Lab Sci, 2005. 35(2): p. 137-43.

[2]. Galvao, R.I., et al., Tenoxicam exerts a neuroprotective action after cerebral ischemia in rats. Neurochem Res, 2005. 30(1): p. 39-46.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA